39
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3 subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously associated with multiple myeloma. To explore the therapeutic potential of HuLuc63 in multiple myeloma, we examined in detail the expression profile of CS1, the binding properties of HuLuc63 to normal and malignant cells, and the antimyeloma activity of HuLuc63 in preclinical models.

          Related collections

          Author and article information

          Journal
          Clin Cancer Res
          Clinical cancer research : an official journal of the American Association for Cancer Research
          American Association for Cancer Research (AACR)
          1078-0432
          1078-0432
          May 01 2008
          : 14
          : 9
          Affiliations
          [1 ] Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
          Article
          14/9/2775 NIHMS688405
          10.1158/1078-0432.CCR-07-4246
          4433038
          18451245
          2c1ea686-654a-4217-95e3-9e45f93a3827
          History

          Comments

          Comment on this article